Welcome to our dedicated page for Appili Ther news (Ticker: APLIF), a resource for investors and traders seeking the latest updates and insights on Appili Ther stock.
Appili Therapeutics Inc. develops anti-infective products for infectious diseases and biodefense. Company updates cover its portfolio of LIKMEZ (ATI-1501), an FDA-approved ready-made metronidazole suspension; ATI-1701, a live-attenuated tularemia vaccine candidate; ATI-1801, a topical antiparasitic program for cutaneous leishmaniasis; and collaborations involving VXV-01, a fungal vaccine program.
Recurring news also addresses non-dilutive government funding, NIAID and U.S. Air Force Academy-supported development work, manufacturing and regulatory activities, financial and operational results, scientific and biodefense conference participation, and shareholder meeting outcomes.
Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) reported its financial results for Q1 2022, ending June 30, 2021. The company incurred a net loss of $7.4 million ($0.12 per share), up from $2.6 million ($0.05 per share) in Q1 2021, largely due to increased R&D expenses. Operationally, it completed an interim analysis for the Phase 3 PRESECO trial of Avigan®/Reeqonus™ for COVID-19, receiving a recommendation to continue. The trial has expanded into Latin America, and the company secured $3.5 million in funding for its pipeline.
Appili Therapeutics (TSX: APLI; OTCQX: APLIF) reported its fiscal year results for 2021, showing a net loss of $14.3 million, up from $5.4 million in 2020. Research and development expenses rose by $8.1 million. The company has $16.1 million in cash and working capital of $13.6 million. Appili is encouraged by the independent monitoring board's recommendation to continue its Phase 3 PRESECO trial for Avigan/Reeqonus, targeting COVID-19. The company aims to advance its pipeline, including a $6.3 million grant for its ATI-1701 vaccine program.
Appili Therapeutics (OTCQX: APLIF) expands its Phase 3 PRESECO clinical trial of Avigan®/Reeqonus™ (favipiravir) for COVID-19 by adding clinical research sites in Mexico and Brazil. This move aims to expedite enrollment and trials completion, with top-line data expected by Q3 2021. The study focuses on a potential home treatment for mild-to-moderate COVID-19 patients. An independent Data and Safety Monitoring Board has recommended proceeding without modifications. The CONTROL trial is ended to prioritize PRESECO, and a future Phase 3 PEPCO study is planned for post-exposure prophylaxis.
Appili Therapeutics (APLIF) announced that the independent Data and Safety Monitoring Board (DSMB) has endorsed the continuation of its Phase 3 PRESECO trial for Avigan/Reeqonus (favipiravir) without modifications. This trial is aimed at evaluating the drug as a potential treatment for mild-to-moderate COVID-19 patients. With approximately 600 subjects involved, Appili expects to report top-line results in Q3 2021. The drug has a well-established safety profile and is part of a consortium aimed at global development for COVID-19 treatment.
Appili Therapeutics (OTCQX:APLIF) announces that CEO Dr. Armand Balboni will present at the Bloom Burton & Co. Healthcare Investor Conference on April 21, 2021, at 10:00 AM ET. The conference is fully virtual, and Appili will conduct one-to-one meetings with attendees. A live webcast of the presentation will be available on the Company’s website, with a replay accessible afterward. Appili focuses on developing anti-infective drug candidates to combat urgent infections worldwide.
Appili Therapeutics (TSX: APLI; OTCQX: APLIF) will present at the Inaugural Emerging Growth Virtual Conference from March 17-19. CEO Dr. Armand Balboni will partake in a Fireside Chat on March 19 at 4:30 PM ET. The presentation is scheduled for March 19 at 2:30 PM ET, with opportunities for one-to-one meetings throughout the conference. Interested investors can register HERE. A replay will be available on Appili’s website after the event.
Appili Therapeutics (TSX: APLI; OTCQX: APLIF) announced a webinar series focusing on infectious diseases, featuring notable experts like Dr. Scott Gottlieb and Dr. Syra Madad. The first event, scheduled for March 3 at 1:00 p.m. ET, will discuss pandemic response strategies and future infectious outbreaks. This initiative aims to enhance understanding and investment in treatments and public health policies. The company continues to support late-stage clinical trials for its antiviral candidate, highlighting its commitment to addressing urgent healthcare needs.
Appili Therapeutics (TSX: APLI; OTCQX: APLIF) announced a webinar series on global infectious disease trends, starting on March 3, 2021, featuring prominent speakers including Dr. Scott Gottlieb and Dr. Syra Madad. The panel will focus on pandemic response strategies, treatment investments, and future infectious disease challenges. The event is free and open to the public with prior registration. Appili Therapeutics is actively involved in developing antiviral treatments, including late-stage trials for Avigan® / REEQONUSTM for COVID-19.
Appili Therapeutics (TSX: APLI; OTCQX: APLIF) will present at the virtual Biocom Global conference from February 23-25, 2021. The presentation will focus on favipiravir, an antiviral therapy approved in Japan for influenza, and its potential use in treating COVID-19, alongside updates on their antifungal compound ATI-2307. The CEO, Armand Balboni, will host one-on-one investor meetings. The event features prominent speakers and highlights the importance of collaboration in addressing patient needs during the pandemic. For more details, visit biocomglobalpartnering.org.
Appili Therapeutics (TSX: APLI; OTCQX: APLIF) has announced a new webinar series focused on global infectious disease trends, starting with an event on March 3, featuring Dr. Scott Gottlieb. The series aims to explore challenges in combating COVID-19, including public health policies and new viral strains. The first session will include a Q&A segment and address the necessity for diverse treatments and public health strategies. Additionally, other events will be scheduled throughout the year, promoting ongoing discussions in the infectious disease sector.